作者
Sung‐Jin Hong,Yong-Joon Lee,Seungjun Lee,Bum‐Kee Hong,Woong Chol Kang,Jong‐Young Lee,Jin-Bae Lee,Tae–Hyun Yang,Junghan Yoon,Chul‐Min Ahn,Jung-Sun Kim,Byeong‐Keuk Kim,Young–Guk Ko,Donghoon Choi,Yangsoo Jang,Myeong–Ki Hong,Myeong–Ki Hong,Donghoon Choi,Young–Guk Ko,Byeong‐Keuk Kim,Jung-Sun Kim,Chul‐Min Ahn,Sung‐Jin Hong,Seungjun Lee,Yong-Joon Lee,Bum‐Kee Hong,Hyuck Moon Kwon,Jong Youn Kim,Pil‐Ki Min,Young Won Yoon,Byoung Kwon Lee,Se Joong Rim,Eui‐Young Choi,Woong Chol Kang,Pyung Chun Oh,Jong‐Young Lee,Jin-Bae Lee,Kee Sik Kim,Ji Yong Choi,Jae Kean Ryu,Seung Pyo Hong,Chang Yeon Kim,Tae–Hyun Yang,Hyung-Jin Cho,Junghan Yoon,Min Soo Ahn,Sung Gyun Ahn,Jun–Won Lee,Jung‐Woo Son,Yangsoo Jang,Hyuck–Jun Yoon,Cheol Hyun Lee,Jongmin Hwang,Yun‐Kyeong Cho,Seung‐Ho Hur,Seongwook Han,Chang‐Wook Nam,Hyoungseop Kim,Hyoung‐Seob Park,In-Cheol Kim,Yun-Hyeong Cho,Hyeon‐Ju Jeong,Jin-Ho Kim,Chewan Lim,Yongsung Suh,Euiseok Hwang,Ji Hyun Lee,Sung Yun Lee,Sung Uk Kwon,Song-Yi Kim,Keun-Ho Park,Hyun Kuk Kim
摘要
In patients with coronary artery disease, some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in low-density lipoprotein cholesterol (LDL-C). An alternative approach is to begin with moderate-intensity statins and titrate to a specific LDL-C goal. These alternatives have not been compared head-to-head in a clinical trial involving patients with known coronary artery disease.To assess whether a treat-to-target strategy is noninferior to a strategy of high-intensity statins for long-term clinical outcomes in patients with coronary artery disease.A randomized, multicenter, noninferiority trial in patients with a coronary disease diagnosis treated at 12 centers in South Korea (enrollment: September 9, 2016, through November 27, 2019; final follow-up: October 26, 2022).Patients were randomly assigned to receive either the LDL-C target strategy, with an LDL-C level between 50 and 70 mg/dL as the target, or high-intensity statin treatment, which consisted of rosuvastatin, 20 mg, or atorvastatin, 40 mg.Primary end point was a 3-year composite of death, myocardial infarction, stroke, or coronary revascularization with a noninferiority margin of 3.0 percentage points.Among 4400 patients, 4341 patients (98.7%) completed the trial (mean [SD] age, 65.1 [9.9] years; 1228 females [27.9%]). In the treat-to-target group (n = 2200), which had 6449 person-years of follow-up, moderate-intensity and high-intensity dosing were used in 43% and 54%, respectively. The mean (SD) LDL-C level for 3 years was 69.1 (17.8) mg/dL in the treat-to-target group and 68.4 (20.1) mg/dL in the high-intensity statin group (n = 2200) (P = .21, compared with the treat-to-target group). The primary end point occurred in 177 patients (8.1%) in the treat-to-target group and 190 patients (8.7%) in the high-intensity statin group (absolute difference, -0.6 percentage points [upper boundary of the 1-sided 97.5% CI, 1.1 percentage points]; P < .001 for noninferiority).Among patients with coronary artery disease, a treat-to-target LDL-C strategy of 50 to 70 mg/dL as the goal was noninferior to a high-intensity statin therapy for the 3-year composite of death, myocardial infarction, stroke, or coronary revascularization. These findings provide additional evidence supporting the suitability of a treat-to-target strategy that may allow a tailored approach with consideration for individual variability in drug response to statin therapy.ClinicalTrials.gov Identifier: NCT02579499.